Page 115 - 2021_12-Haematologica-web

SF3B1 mutations and NOTCH1 activation in CLL
quency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia. PLoS One. 2015;10(11):e0143073.
32. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121(3):468-475.
33. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic sub- type: a study of quantitative flow cytome- try and fluorescent in-situ hybridization in 510 patients. Br J Haematol. 2008; 141(1):36-40.
34. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992;40(4):259-263.
35. Marti GE, Faguet G, Bertin P, et al. CD20 and CD5 expression in B-chronic lympho- cytic leukemia. Ann N Y Acad Sci. 1992; 651:480-483.
36. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(9):3118-3123.
37. Axelrod JD, Matsuno K, Artavanis- Tsakonas S, Perrimon N. Interaction between Wingless and Notch signaling pathways mediated by dishevelled. Science. 1996;271(5257):1826-1832.
38. Munoz-Descalzo S, Sanders PG, Montagne C, Johnson RI, Balayo T, Arias AM. Wingless modulates the ligand independent traffic of Notch through Dishevelled. Fly
(Austin ). 2010;4(3):182-193.
39. Collu GM, Hidalgo-Sastre A, Acar A, et al.
Dishevelled limits Notch signalling through inhibition of CSL. Development. 2012; 139(23):4405-4415.
40. Hayward P, Kalmar T, Arias AM. Wnt/Notch signalling and information pro- cessing during development. Development. 2008;135(3):411-424.
41. Hallek M. On the architecture of transla- tional research designed to control chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2018;(1):1-8.
42. Delgado J, Matutes E, Morilla AM, et al. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol. 2003;120(5):754-759.
43. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609-1613.
44. Tomita A. Genetic and epigenetic modula- tion of CD20 expression in B-cell malignan- cies: molecular mechanisms and signifi- cance to rituximab resistance. J Clin Exp Hematop. 2016;56(2):89-99.
45. Castel D, Mourikis P, Bartels SJ, Brinkman AB, Tajbakhsh S, Stunnenberg HG. Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 2013;27(9):1059-1071.
46.Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal muta- tions in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
47. Arruga F, Vaisitti T, Deaglio S. The NOTCH pathway and its mutations in mature B cell malignancies. Front Oncol. 2018;8:550.
48. Wang H, Zou J, Zhao B, et al. Genome- wide analysis reveals conserved and diver- gent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(36):14908-14913.
49. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and ritux- imab treatment achieves long-term disease- free survival in IGHV-mutated chronic lym- phocytic leukemia. Blood. 2016;127(3):303- 309.
50. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remis- sion after first-line fludarabine-cyclophos- phamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921-1924.
51.Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019; 133(10):1011-1019.
52. Ten Hacken E, Valentin R, Regis FFD, et al. Splicing modulation sensitizes chronic lym- phocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018;3(19): e121438.
53. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
54. Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135(26):2402-2412.
haematologica | 2021; 106(12)
3135